2型糖尿病对非小细胞肺癌预后的影响。
Impact of Type 2 Diabetes Mellitus on the Prognosis of Non-Small Cell Lung Cancer.
作者信息
Lu You, Hu Yaohua, Zhao Yi, Xie Shuanshuan, Wang Changhui
机构信息
Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200025, China.
出版信息
J Clin Med. 2022 Dec 31;12(1):321. doi: 10.3390/jcm12010321.
OBJECTIVE
Type 2 diabetes mellitus (T2DM) is the most common metabolic disease and is characterized by sustained hyperglycemia. The impact of T2DM on the survival of lung cancer patients remains controversial. The aim of this study was to investigate the associations of type 2 diabetes with lung cancer mortality.
METHODS
From January 2019 to January 2020, 228 patients with non-small cell lung cancer (NSCLC) staging earlier than IIIA were included.
RESULTS
In our study, we found that the overall survival (OS) and progression-free survival (PFS) of lung cancer patients with diabetes was longer than non-diabetes group. Diagnosed T2DM was associated with the prognosis of lung cancer after adjusting for age and covariates. The association between T2DM and OS was influenced by age, stage of cancer and cancer treatment, as well as whether taking metformin was associated with the OS of lung cancer. However, with the adjustment for age and covariates, the relation trended to lose statistical significance.
CONCLUSION
T2DM is an independent prognostic factor for patients with NSCLC staging before IIIA. The patients with both NSCLC and T2DM trended to having a longer OS, possibly due to metformin.
目的
2型糖尿病（T2DM）是最常见的代谢性疾病，其特征为持续性高血糖。T2DM对肺癌患者生存率的影响仍存在争议。本研究旨在探讨2型糖尿病与肺癌死亡率之间的关联。
方法
纳入2019年1月至2020年1月期间228例非小细胞肺癌（NSCLC）分期早于IIIA期的患者。
结果
在我们的研究中，我们发现糖尿病肺癌患者的总生存期（OS）和无进展生存期（PFS）比非糖尿病组更长。在调整年龄和协变量后，确诊的T2DM与肺癌预后相关。T2DM与OS之间的关联受年龄、癌症分期和癌症治疗影响，以及是否服用二甲双胍与肺癌OS相关。然而，在调整年龄和协变量后，这种关系趋于失去统计学意义。
结论
T2DM是IIIA期之前NSCLC患者的独立预后因素。NSCLC和T2DM患者的OS往往更长，可能归因于二甲双胍。
Zotero 插件